SEARCH:   Advanced

Blood, 15 October 2006, Vol. 108, No. 8, pp. 2540-2544. Prepublished online as a Blood First Edition Paper on July 11, 2006; DOI 10.1182/blood-2006-03-013193. This Article Full Text (PDF) All Versions of this Article: blood-2006-03-013193v1 108/8/2540    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Sebban, C. Articles by Coiffier, B. Search for Related Content PubMed PubMed Citation Articles by Sebban, C. Articles by Coiffier, B. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 31, 2006 Accepted May 9, 2006 Standard chemotherapy with interferon compared to CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the GELA Catherine Sebban*, Nicolas Mounier, Nicole Brousse, Coralie Belanger, Pauline Brice, Corinne Haioun, Herve Tilly, Pierre Feugier, Redah Bouabdallah, Chantal Doyen, Gilles Salles, and Bertrand Coiffier Centre Leon Berard, Lyon, France Hopital Saint-Louis, Paris, France Hopital Necker, Paris, France CHU Henri Mondor, Creteil, France Centre Becquerel, Rouen, France CHU de Brabois, Nancy, France Institut Paoli Calmette, Marseille, France Universite Catholique de Louvain, Yvoir, Belgium Hospices Civils de Lyon, Pierre-Benite, France * Corresponding author; email: sebban{at}lyon.fnclcc.fr. To compare our standard chemotherapy regimen (CHVP) plus interferon with 4 courses of CHOP followed by high-dose therapy with autologous stem cell transplantation (ASCT) in treatment-naive patients with advanced follicular lymphoma. 401 patients were included from 07/94 to 03/01: 209 received 12 cycles of CHVP (cyclophosphamide, doxorubicin, teniposide, and prednisone) plus interferon alfa for 18 months (CHVP-I arm) and 192 received 4 cycles of CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by high-dose therapy with total body irradiation and ASCT (CHOP-HDT arm). Overall response rates were similar in both groups (79% and 78% after induction chemotherapy, respectively). 131 of the150 patients eligible for HDT underwent transplantation (87%). Intent to treat analysis after a median follow-up of 7.5 years showed that there was no difference between the 2 arms for overall survival (p=0.53) and event-free survival (p=0.11). Patients with a complete response at the end of the induction therapy had a statistically longer event-free survival and overall survival (p=0.02 and 0.0009, respectively). After long-term follow-up, our study showed that there was no statistically significant benefit in favor of first line high-dose therapy in patients with follicular lymphoma. High-dose therapy should be reserved for relapsing patients. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Autologous transplantation for follicular lymphoma? Not too soon! Koen van Besien Blood 2006 108: 2496-2497. [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020